Progress in the Development of VistaGen’s (VSTA) AV-101 Prodrug Candidate for Treating Neuropathic Pain and Depression
With grant funding from the U.S. National Institutes of Health (NIH), biotechnology company VistaGen Therapeutics, Inc. has successfully completed Phase…